These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 31005428)

  • 1. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
    Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
    Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
    Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
    PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
    LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
    Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
    BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
    Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
    PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
    Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era.
    de Miguel S; Domenech M; González-Camacho F; Sempere J; Vicioso D; Sanz JC; Comas LG; Ardanuy C; Fenoll A; Yuste J
    Clin Infect Dis; 2021 Dec; 73(11):e3778-e3787. PubMed ID: 32990303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
    PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the changing pneumococcal national immunisation program among older Australians.
    Menzies R; Stein AN; Booy R; Van Buynder PG; Litt J; Cripps AW
    Vaccine; 2021 Jan; 39(4):720-728. PubMed ID: 33384189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
    Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).
    Meiring S; Cohen C; Quan V; de Gouveia L; Feldman C; Karstaedt A; Klugman KP; Madhi SA; Rabie H; Sriruttan C; von Gottberg A;
    PLoS One; 2016; 11(2):e0149104. PubMed ID: 26863135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is It Time To Review The Vaccination Strategy To Protect Adults Against Invasive Pneumococcal Disease?
    Corcoran M; Mereckiene J; Murchan S; McElligott M; ’Flanagan D; Cotter S; Cunney R; Humphreys H
    Ir Med J; 2019 Mar; 112(3):894. PubMed ID: 30968681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for pneumococcal vaccination in older adults in the coming era.
    Nakashima K; Fukushima W
    Hum Vaccin Immunother; 2024 Dec; 20(1):2328963. PubMed ID: 38517265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18.
    Pick H; Daniel P; Rodrigo C; Bewick T; Ashton D; Lawrence H; Baskaran V; Edwards-Pritchard RC; Sheppard C; Eletu SD; Rose S; Litt D; Fry NK; Ladhani S; Chand M; Trotter C; McKeever TM; Lim WS
    Thorax; 2020 Jan; 75(1):38-49. PubMed ID: 31594801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
    Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
    Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan.
    Riaz A; Mohiuddin S; Husain S; Yousafzai MT; Sajid M; Kabir F; Rehman NU; Mirza W; Salam B; Nadeem N; Pardhan K; Khan KMA; Raza SJ; Arif F; Iqbal K; Zuberi HK; Whitney CG; Omer SB; Zaidi AKM; Ali A;
    Int J Infect Dis; 2019 Mar; 80():28-33. PubMed ID: 30576865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.